• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Dec 3;110126.
doi: 10.1016/j.celrep.2021.110126. Online ahead of print.
IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus


Yang Yu[SUP] 1 [/SUP], Na Xu[SUP] 2 [/SUP], Qi Cheng[SUP] 3 [/SUP], Fei Deng[SUP] 4 [/SUP], Meiqin Liu[SUP] 5 [/SUP], Airu Zhu[SUP] 6 [/SUP], Yuan-Qin Min[SUP] 4 [/SUP], Dan Zhu[SUP] 7 [/SUP], Wenbo Huang[SUP] 6 [/SUP], Xu Feng[SUP] 2 [/SUP], Xizhong Jing[SUP] 1 [/SUP], Ying Chen[SUP] 5 [/SUP], Daoyuan Yue[SUP] 8 [/SUP], Yawei Fan[SUP] 3 [/SUP], Chang Shu[SUP] 3 [/SUP], Qing Guan[SUP] 8 [/SUP], Zifeng Yang[SUP] 6 [/SUP], Jincun Zhao[SUP] 6 [/SUP], Wenjun Song[SUP] 9 [/SUP], Deyin Guo[SUP] 1 [/SUP], Huanliang Liu[SUP] 10 [/SUP], Jindong Zhao[SUP] 11 [/SUP], Ping Lan[SUP] 12 [/SUP], Zhengli Shi[SUP] 13 [/SUP], Yingfang Liu[SUP] 14 [/SUP], Xiaoping Chen[SUP] 15 [/SUP], Huanhuan Liang[SUP] 16 [/SUP]



Affiliations

Abstract

Previous studies have shown that the high mortality caused by viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus primarily results from complications of a cytokine storm. Therefore, it is critical to identify the key factors participating in the cytokine storm. Here we demonstrate that interferon-induced protein 35 (IFP35) plays an important role in the cytokine storm induced by SARS-CoV-2 and influenza virus infection. We find that the levels of serum IFP35 in individuals with SARS-CoV-2 correlates with severity of the syndrome. Using mouse model and cell assays, we show that IFP35 is released by lung epithelial cells and macrophages after SARS-CoV-2 or influenza virus infection. In addition, we show that administration of neutralizing antibodies against IFP35 considerably reduces lung injury and, thus, the mortality rate of mice exposed to viral infection. Our findings suggest that IFP35 serves as a biomarker and as a therapeutic target in virus-induced syndromes.

Keywords: COVID-19; IFP35; biomarker and therapeutic target; cytokine storm; influenza virus.
 
Back
Top Bottom